As parents clamor for a treatment touted for autism, doctors hesitate to prescribe it

Prescriptions for leucovorin spiked 71% in Q4 2025 after federal messaging promoted the drug; the FDA then narrowed its position, limiting use to FOLR1-related cerebral folate transport deficiency (an extremely rare condition with <50 identified cases). The oral drug has been in shortage since November, prompting the FDA to allow imports from Canada and raising the risk of price pressure and supply constraints for oncology patients. Private clinics and proponents are monetizing demand (initial visit fees reported up to $1,896) and a physician-founded company disclosed a $100,000 raise, indicating a fragmented paid market with regulatory, safety and reputational risks.

Analysis

This is primarily a supply/demand shock routed through the prescription channel rather than a durable change in clinical practice. Expect a short-to-medium term uplift in procurement and margin capture for national wholesalers and specialty distributors as they arbitrate constrained supply — reaction time for inventory rebuild is weeks-to-months, while contracting and import licensing can take 1–3 quarters. That creates a transient profit opportunity but also concentrates reputational and regulatory risk on players who scale supply rapidly.

Clinically and regulatory, the story creates two distinct pools of demand: patients who will accept an evidence-gating process (testing, specialist confirmation) and patients willing to pay out-of-network for access. Payers and large systems are incentivized to harden prior-authorization and diagnostic-gating rules within 3–12 months; diagnostics companies that can credibly claim validated genetic/metabolic testing for relevant folate-pathway phenotypes are positioned to capture that gating spend. Conversely, high-fee private prescribers and compounding pharmacies can monetize unmet demand but are exposed to fast-moving enforcement, shortage-driven price volatility, and professional backlash.

Market catalysts to watch are (1) formal payer policy changes and coding guidance (weeks–months), (2) new randomized trial data or major journal re-analyses (months–years), and (3) public supply/shortage notices or import permits (days–weeks). Each catalyst has asymmetric outcomes: favorable diagnostic guidelines create sustainable revenue streams for testing providers; continued regulatory skepticism or concrete safety/shortage issues would reverse demand sharply and compress any temporary distributor premium.

Key Decisions for Investors

• Long national pharmaceutical distributors (e.g., MCK or ABC) — 1–2% position sized trade, 3–6 month horizon. Rationale: temporary margin capture from arbitraging constrained supply and import flows. Risk/reward: modest upside (5–15%) if shortages persist; downside 8–12% if supply normalizes or regulatory scrutiny forces price concessions.
• Long specialty diagnostics names focused on neurodevelopmental panels (e.g., NVTA or MYGN) — 1% position, 6–12 month horizon. Rationale: payer gating and clinician demand for molecular/functional testing could formalize, creating durable higher-margin volume. Risk/reward: asymmetric upside (10–30% revenue re-rating if testing becomes standard) vs binary downside (insurer noncoverage or null results limiting adoption).
• Tactical options trade: buy 3–6 month call spreads on a large distributor (MCK or ABC) ahead of expected supply/shortage announcements — low-cost directional play to capture binary upside if shortages worsen. Risk: time decay; reward: 2–4x if announcement tightens supply or import channels remain constrained.
• Avoid/underweight pure-play telehealth names (TDOC) as a destination for transactionary prescribing demand; instead, rotate into in-person specialty clinic exposure through local healthcare services or integrated pharmacy chains (CVS) — 3–6 month reallocation. Rationale: telehealth monetizes access but insurers/payers and hospital networks are more likely to retain long-term diagnostic spend; risk: telehealth could still capture short-term volume, so limit exposure.